The Paper's reporter Li Xiaoxiao
"There is a lot of news on the Internet, and I think everyone is waiting for the final results of the Medical Insurance Bureau, but one thing I can be sure of is that Hengrui Pharmaceutical must be very active in the negotiation of medical insurance."
On December 19, Hengrui Pharmaceutical (600276. SH) held a press conference in Shanghai on the research results of the PD-1 anti-cancer drug carellizumab antibody lung cancer, at which Zou Jianjun, deputy general manager and chief medical officer of Hengrui Pharmaceutical, answered questions about the fifth round of medical insurance negotiations that have just concluded.
Zou Jianjun said that the final result of the medical insurance negotiations should still be subject to the results announced by the National Medical Insurance Bureau. She also mentioned that if carellizumab can enter the medical insurance at a very reasonable price, it is believed that it can bring more benefits to patients in China.
The scene of the press conference on the research results of carried out on lung cancer in the field of carellizumab
It is reported that in the medical insurance negotiations that ended on December 16, there are 7 major products competing for single PD-1 broad-spectrum anti-cancer drugs, of which there are 4 kinds of domestic products, and The Carelli beads of Hengrui Pharmaceutical are one of them.
Talking about the advantages of Hengrui Pharmaceutical Carelli Beads, Zou Jianjun told the surging news that Carelli Beads have 4 major indications, the most important of which are liver cancer, esophageal cancer, and lung cancer, all of which belong to China's high-incidence tumor species, and are the only PD-1 drugs with several major indications in China.
Zou Jianjun also added that next year carellizumab will publish updated research results, "which will definitely give us more confidence." ”
At the press conference, Hengrui Pharmaceutical announced that the global academic journal "The Lancet-Respiratory Medicine" published online the success of the study of "carellizumab plus carboplatin and pemetrexed compared with chemotherapy alone in the first-line treatment of advanced nonsquamous non-small cell lung cancer (CameL study)".
Zhou Caiyong, director of the Department of Oncology of Shanghai Pulmonary Hospital, introduced at the press conference that CameL research data showed that the median survival of carellizumab combined with chemotherapy in the first-line treatment of advanced non-squamous non-small cell lung cancer was as long as 27.9 months. This data is the longest survival benefit data in the clinical study of similar lung cancer immunotherapy in the world so far, breaking the two-year mark.
Zhou Caicun also introduced that the first-line treatment of carelizumab combined with chemotherapy drove gene-negative advanced non-squamous non-small cell lung cancer, the objective response rate was as high as 60.5%, and the median progression-free survival was as long as 11.3 months.
PD-1 anti-cancer drugs are the use of the body's own immune system to deal with tumors, for the adverse reactions of PD-1 drugs that have attracted much attention from patients, Zhou Caicun told the surging news, as a doctor, you must choose drugs with good efficacy, mild toxic side reactions, and accurate efficacy to treat lung cancer. From the current data, there are fewer severe adverse reactions, such as immune-related pneumonia, hepatitis, myocarditis, and the most important adverse reaction is reactive capillary hyperplasia, but this does not produce fatal death for patients.
For the medical insurance negotiations, Zhou Caicun also expressed his views to the surging news. He said that from the doctor's point of view, he has done a good job of research, has good data, and hopes that more patients can use it and can afford it.
"I hope that carellizumab can enter medical insurance, at least the medical insurance for lung cancer hopes to get it, because lung cancer is the first major cancer, you control lung cancer, other tumors can definitely be solved." Zhou Caicun said.
Editor-in-Charge: It's Winter
Proofreader: Liu Wei